Prasad Narayanan
Research Subjects
Prasad Narayanan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
A. K. Rathi
Department of Radiation Oncology, Lok Nayak Hospital, New Delhi, India
1 shared publicationAmit Bhargava
Department of Medical Oncology, Fortis Hospital, New Delhi, India
1 shared publicationAtul Sharma
Department of Medical Oncology, Max Superspeciality Hospital, New Delhi, India
1 shared publicationBrig H. P. Singh
Department of Medical Oncology, Park Hospital, Mohali, Punjab, India
1 shared publicationC. Selvasekar
Clinical Services & Specialist Surgery, The Christie NHS Foundation Trust, Manchester, United Kingdom
1 shared publicationH. S. Darling
Department of Medical Oncology, Air Force Hospital, Jorhat, Assam, India
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 13 (04) , 281-286
Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More
A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.K., Denmark, Spain, Sweden, Australia, New Zealand), TOSCA (Italy), Alliance/SWOG80702 (U.S., Canada), IDEA (France), ACHIEVE (Japan), and HORG (Greece). Management recommendation is also based on patient preferences, dividing them into fighters and fatalists. Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients—especially due to their limited mobility, comorbidities, and polypharmacy.
- 1 October 2024
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 13 (04) , 281-286
Open AccessAdjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More
A significant number of patients with colorectal cancer (CRC) benefit from adjuvant therapy. While 6 months of FOLFOX is standard of care, newer regimens like CAPOX and SOX allow for shorter durations. Trials of importance include SCOT (U.K., Denmark, Spain, Sweden, Australia, New Zealand), TOSCA (Italy), Alliance/SWOG80702 (U.S., Canada), IDEA (France), ACHIEVE (Japan), and HORG (Greece). Management recommendation is also based on patient preferences, dividing them into fighters and fatalists. Better patient selection is possible with the use of novel molecular-based biomarkers and circulating tumor deoxyribonucleic acid monitoring of minimal residual disease. There also needs to be special consideration for the geriatric patients—especially due to their limited mobility, comorbidities, and polypharmacy.
- Open Access
- 1 October 2013
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 02 (04) , 272-277
Denosumab: A comprehensive review
The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that tumor cells interact within the bone to stimulate the receptor activator of nuclear factor kB (RANK)-RANK ligand (RANKL) pathway. RANKL is an essential mediator of osteoclast formation, function, and survival. Because of the central role of RANKL in cancer-induced bone destruction, the inhibition of RANKL has the potential to result in the reduction of pathologic bone resorption. Denosumab is a fully human monoclonal antibody specific for RANKL that inhibits the formation, activation, and survival of osteoclasts. This in turn decreases bone resorption and reduces cancer-induced bone destruction. In this review, we give an overview of the drug Denosumab with its history, mechanism of action, clinical trial data, adverse effects, and future challenges.
- 1 October 2013
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 02 (04) , 272-277
Open AccessDenosumab: A comprehensive review
The clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that tumor cells interact within the bone to stimulate the receptor activator of nuclear factor kB (RANK)-RANK ligand (RANKL) pathway. RANKL is an essential mediator of osteoclast formation, function, and survival. Because of the central role of RANKL in cancer-induced bone destruction, the inhibition of RANKL has the potential to result in the reduction of pathologic bone resorption. Denosumab is a fully human monoclonal antibody specific for RANKL that inhibits the formation, activation, and survival of osteoclasts. This in turn decreases bone resorption and reduces cancer-induced bone destruction. In this review, we give an overview of the drug Denosumab with its history, mechanism of action, clinical trial data, adverse effects, and future challenges.